((自动化翻译由路透提供，请见免责声明 ))
9月24日 - ** 基因疗法生产商蓝鸟生物 的 股价盘前上涨2.3%至49美分；上一交易日上涨1%。
** 该公司称 (link)，作为重组的一部分，它将裁员约 25%，以优化现金流，在 2025 年下半年实现收支平衡。
** 重组还将使运营现金支出减少 20%--该公司称，将在 2025 年下半年实现现金流收支平衡。
** BLUE 表示，重组将导致总计价值 370 万美元的支出，将在截至 12 月 31 日的财年内支付。
** 截至 2024 年 6 月 30 日，公司共有 375 名全职员工
** 截至上次收盘，股价累计下跌 64.6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.